Physostigmine as a discriminative cue in rats

Area of Science:

• Neuroscience
• Pharmacology
• Behavioral Science

Background:

• Physostigmine is a reversible cholinesterase inhibitor with known central nervous system effects.
• Drug discrimination studies are crucial for understanding the central mechanisms of psychoactive compounds.

Purpose of the Study:

• To investigate the central action site of physostigmine using a drug discrimination paradigm in rats.
• To examine the interaction between physostigmine and the anticholinergic drug ditran on learned behavioral responses.

Main Methods:

• Rats were trained to discriminate between the presence and absence of physostigmine (0.50 mg/kg) in a T-maze.
• The effect of co-administering physostigmine with varying doses of ditran (0.80–3.20 mg/kg) was assessed.
• Neostigmine (0.50 mg/kg), a quaternary anticholinesterase, was tested for its discriminative properties.

Main Results:

• Rats successfully acquired the physostigmine discrimination task.
• Simultaneous administration of physostigmine and ditran reversed the established drug discrimination.
• Neostigmine failed to produce a discriminative effect, suggesting a central, not peripheral, site of action for physostigmine.

Conclusions:

• The findings support a central site of action for physostigmine's discriminative stimulus properties.
• Anticholinergic agents like ditran can modulate or reverse established physostigmine-induced behavioral effects.
• This study highlights the utility of drug discrimination in elucidating the neurochemical underpinnings of drug action.